Pyrazinoylguanidine in end-stage renal disease: a prospective, placebo-controlled pilot study.
Cardiovascular disease is the leading cause of mortality in end-stage renal disease (ESRD) patients receiving dialysis. In these patients, hypertriglyceridemia appears to increase the risk of accelerated atherosclerosis. The present placebo-controlled study evaluated prospectively lipid-lowering effects of pyrazinoylguanidine (PZG) in 6 ESRD patients undergoing maintenance hemodialysis. The design of the study entailed a placebo phase of 1 week followed by 3 weeks of PZG, 400 mg three times a day. Compared to placebo, PZG reduced serum triglycerides (PZG vs. placebo 370 +/- 171 vs. 414 +/- 182 mg/dl; p = 0.01). PZG also tended to decrease total cholesterol. In addition, PZG selectively lowered blood glucose in hyperglycemic patients. PZG was well tolerated; it did not interfere with hemodynamic parameters or alter liver function tests, nutritional parameters or dialysis clearance.
Ahsan
N
N
Department of Medicine, The Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Korsunsky
Z
Z
Beyer
K H
KH
Vesell
E S
ES
D000284:Administration, Oral; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D005260:Female; D006146:Guanidines / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy; D015228:Hypertriglyceridemia / Q000188:drug therapy* / Q000209:etiology; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D006435:Renal Dialysis; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D006146:Guanidines; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D011719:Pyrazines; D014280:Triglycerides; C056104:2-pyrazinoylguanidine; D002784:Cholesterol